AKT1 and cancer: Drugs such as NB7M that can block Akt, PI-3K, survival kinase IKKα and transcription factor NF-κB activities, which are known to contribute to tumour growth by promoting cell-cycle entry, cell proliferation, cell migration, or antiapoptotic responses, and are implicated in resistance to radio- and chemotherapy (Kip et al, 2002; Greten and Karin, 2004), are potential cancer therapeutics.